Mayo Clinic Develops New Blood Test for Detecting Testicular Cancer Missed by Standard Methods
Mayo Clinic researchers have introduced a new blood-based diagnostic method aimed at detecting germ cell tumors, the most common form of testicular cancer, which are often missed by standard blood tests. This new test, called GCT-iSIGN, analyzes thousands of immune system signals in the blood simultaneously. In a study involving 427 blood samples, the test successfully identified 93% of individuals with germ cell tumors and accurately ruled out cancer in 99% of those without it. The test also detected 23 out of 24 cases that standard tests failed to identify. Additionally, a second test, Sem-iSIGN, was developed to differentiate between two main types of testicular cancer, which is crucial for determining the appropriate treatment approach. The research, published in Nature Communications, was led by M. Bakri Hammami, M.D., and Andrew M. Knight, Ph.D., with funding from the Department of Defense and other sources.